# Clinical Trial to Evaluate the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type I

> **NCT06576388** · EARLY_PHASE1 · COMPLETED · sponsor: **Guangzhou Jiayin Biotech Ltd** · enrollment: 2 (actual)

## Conditions studied

- Type I Spinal Muscular Atrophy

## Interventions

- **DRUG:** EXG001-307 injection

## Key facts

- **NCT ID:** NCT06576388
- **Lead sponsor:** Guangzhou Jiayin Biotech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-21
- **Primary completion:** 2023-09-21
- **Final completion:** 2024-01-21
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06576388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06576388, "Clinical Trial to Evaluate the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type I". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06576388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*